Novo Nordisk appoints new president and CEO as it focuses on U.S. weight-loss drug market
Novo Nordisk appointed Maziar Mike Doustdar as its new CEO and president on August 7, 2025, signalling a strategic shift to address challenges in the U.S. weight-loss drug market and competition from Eli Lilly. Doustdar, the first non-Danish leader in the company’s history, emphasised refocusing on the firm’s core strengths in obesity and diabetes while trimming its pipeline to prioritize speed and execution. His…